News Celgene MS pill can't beat older rival on disability progres... Phase 3 trial meets main efficacy endpoint, but disability progression stats cause concern.
News Novartis cues up Cosentyx as disease-modifying treatment for... Pharma begins early intervention trial after Cosentyx shows "disease modifying" properties
GlaxoSmithKline GSK's new CEO Walmsley paid 25% less than predecessor Witty GlaxoSmithKline (GSK) has confirmed rumours that its incoming CEO Emma Walmsley will be paid less than her predecessor, Sir Andrew Witty.
News Next gen psoriasis drugs show superiority to Stelara Guselkumab can also be used if older drug Stellara fails.
News Celgene files AML pill after fast-track trial The FDA has accepted Celgene’s filing for enasidenib.
Views & Analysis Orphan drugs will fuel pharma's future - and a pricing pushb... Evaluate predicts sales could approach $8bn if approved.
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.